ArticleMicrobial genomics2026
A scalable and cost-effective nanopore workflow for 16S rRNA microbiome profiling validated in a zebrafish gut model.
Article in Microbial genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advancements in long-read sequencing technologies, such as those developed by Oxford Nanopore Technologies (ONT), have opened new possibilities for 16S rRNA gene profiling of microbial communities by enabling full-length sequencing. In this study, we optimized and validated a cost-effective, in-house ONT workflow for zebrafish gut microbiome analysis and compared its performance to the gold-standard Illumina NovaSeq platform. Using a PCR-based barcoding strategy, we successfully sequenced both the V3-V4 and V1-V9 regions of the 16S rRNA gene, achieving high read accuracy and balanced demultiplexing across samples. Our results demonstrate that ONT short-read (V3-V4) sequencing using the latest V14 chemistry and Dorado basecaller achieves resolution comparable to that of Illumina, supporting amplicon sequence variant classification. Rarefaction analysis confirmed that the sequencing depth (~240,000 reads/sample) was sufficient to capture microbial diversity in the zebrafish gut, a complex and taxonomically rich environment. Furthermore, taxonomic classifications and diversity metrics were consistent between platforms, supporting the reliability of ONT for microbiota profiling. While full-length (V1-V9) ONT sequencing yielded higher taxonomic richness through operational taxonomic units, it did not significantly improve species-level resolution, likely due to current database and bioinformatics limitations. Our custom library preparation protocol simplified multiplexing, reduced costs and improved scalability without compromising accuracy. Although 15 samples were conservatively multiplexed per flow cell in this study, the workflow has since been applied to larger-scale datasets with up to 75 samples per run and to additional amplicon targets, demonstrating its portability and adaptability across diverse biological contexts. These findings position ONT as a viable, scalable and field-deployable alternative to Illumina for microbiome research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.